Learn how erenumab (Aimovig), a CGRP receptor‑blocking monoclonal antibody, differs from traditional migraine drugs like beta‑blockers and antidepressants. Explore its targeted mechanism, once‑monthly dosing, and clinical trial results for episodic and chronic migraine prevention.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs